News | May 11, 2009

Medtronic Announces U.S. Trial of Device to Close the Left Atrial Appendage

May 11, 2009 - Medtronic Inc. today announced the successful implant of its Cardioblate Closure Left Atrial Appendage Occlusion Device by Patrick McCarthy, M.D., co-director of the Bluhm Cardiovascular Institute at Northwestern Memorial Hospital in Chicago, Ill., as part of a U.S. clinical trial.

The study is being conducted under an investigational device exemption (IDE) and the device is limited to investigational use in the U.S.

Published literature suggests the left atrial appendage (LAA) is the main source of clots coming from the left atrium. Patients with an arrhythmia known as atrial fibrillation (AF) have an increased risk of clot formation as a result of the uncoordinated and fast beating of the heart’s upper chambers, which may lead to blood pooling in the LAA. AF is a recognized independent risk factor for stroke and approximately 35 percent of patients with this irregular heart rhythm will have a stroke during their lifetime.

The trial involves five U.S. centers and will evaluate occlusion of the left atrial appendage with the Cardioblate Closure device in patients undergoing valve replacement, valve repair or coronary bypass surgery.

“The clinical community urgently needs safe and proven therapies to achieve permanent closure of the left atrial appendage,” said Dr. McCarthy, the clinical trial’s principal investigator. “Designed to enable easy positioning for safe and complete occlusion of the left atrial appendage, this new device shows considerable promise.”

Unlike competitor alternatives, Medtronic’s Cardioblate Closure device is intended to occlude the LAA permanently without the need to enter the heart and does not introduce man-made materials into the blood stream. It is designed to be pliable and atraumatic to ensure no collateral damage to surrounding structures of the heart, unlike rigid epicardial occlusion devices.

For more information: www.medtronic.com

Related Content

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Cardiovascular Clinical Studies | August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init